Tesamorelin vs CJC-1295: Two GHRH Analogues, Two Very Different Evidence Bases

Tesamorelin and CJC-1295 are both GHRH analogues. They act on the same receptor, in the same tissue, to produce the same immediate effect. And the evidence behind them is not remotely comparable. One has an approved indication, a completed phase 3 programme and published trial data in hundreds of patients. The other has almost no controlled human evidence at all.

That contrast is the most useful thing in this catalogue for understanding how to weigh a research compound, because it isolates the variable. When two molecules share a mechanism, any difference in what is actually known about them comes down to what was studied — not to how the mechanism sounds.

What a GHRH analogue does

Growth-hormone-releasing hormone is a hypothalamic peptide that acts on the GHRH receptor on somatotroph cells in the anterior pituitary, prompting them to release stored growth hormone. GH in turn acts on the liver to raise IGF-1, which mediates much of what is conventionally attributed to GH itself.

A GHRH analogue supplies no growth hormone. It prompts the pituitary to release its own. This is a meaningful distinction: release remains subject to the body's existing feedback control, including somatostatin's inhibitory tone, so the resulting pattern is pulsatile rather than a sustained elevation. Whether that matters is exactly the sort of question a trial exists to answer.

Native GHRH is useless as a compound because it is degraded within minutes — dipeptidyl peptidase-4 (DPP-4) cleaves it near the N-terminus almost immediately. Every synthetic GHRH analogue is, in essence, a solution to that one problem. They differ in how they solve it.

Tesamorelin: stabilising the full-length molecule

Tesamorelin is a synthetic analogue of full-length human GHRH(1-44) carrying a trans-3-hexenoyl group attached to the N-terminus. That modification is what blocks DPP-4 cleavage, extending the molecule's useful life while leaving the receptor-binding behaviour of native GHRH essentially intact.

It was approved by the FDA in 2010, under the name Egrifta, for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. That approval rests on two randomised, placebo-controlled phase 3 trials published in The New England Journal of Medicine and JAIDS, which reported reductions in visceral adipose tissue measured by CT alongside expected increases in IGF-1.

It has since been investigated in other settings, including non-alcoholic fatty liver disease in people with HIV and, separately, cognition in mild cognitive impairment. Those are smaller studies in defined populations, and they are the boundary of what has been shown — not a general statement about the compound.

CJC-1295: a fragment with a different half-life strategy

CJC-1295 takes the opposite approach. It is based on GHRH(1-29) — the shortest fragment that retains receptor activity — with amino acid substitutions that resist degradation. The DAC version adds a drug affinity complex, a maleimide group that binds covalently to circulating albumin, extending the half-life from minutes to days.

Mechanistically this is elegant. Evidentially it is thin: the published human work amounts to small early-phase pharmacokinetic and pharmacodynamic studies establishing that the compound raises GH and IGF-1 and persists in circulation. There is no phase 3 programme, no approved indication, and no trial designed to measure a clinical outcome. The mechanism is not in doubt. What it produces in a person over time has simply not been tested at that level. The DAC modification itself is covered in CJC-1295 with DAC vs without.

What the comparison actually teaches

Both compounds bind the GHRH receptor. Both raise GH and IGF-1. If mechanism determined what is known, they would be equally well characterised. They are not, and the gap has nothing to do with the biology:

• Approval is evidence, not endorsement. Tesamorelin's approval tells you a specific endpoint was met in a specific population — visceral fat in HIV lipodystrophy. It is not a general statement, and it does not transfer to other populations or purposes.
• Surrogate markers are not outcomes. Both compounds reliably raise IGF-1. IGF-1 is a marker of GH axis activity, not a result anyone cares about for its own sake. A study reporting only that a compound raised IGF-1 has confirmed the mechanism worked, nothing more.
• Absence of evidence is not evidence of absence. CJC-1295's thin record does not mean it does nothing. It means the studies that would tell you have not been run.

Regulatory status in Australia

Tesamorelin is a prescription-only medicine in the jurisdictions where it is approved, and GHRH analogues fall within Schedule 4 territory under the Australian Poisons Standard. TXLABS supplies this compound strictly as a research reference material for laboratory use only. It is not supplied as a medicine, it is not for human or veterinary use, and nothing here is dosing guidance or a suggestion of use. The Australian framework is set out on peptide regulations in Australia.

For the wider family context, see how peptides work. To check what documentation exists for a specific lot before anything else matters, see how to vet a certificate of analysis.